Randall Goldfish
Family Medicine · Kearney, NENPI 1922238732
Payments from drug & device makers
Across 362 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$856
- Johnson & Johnson$519
- AstraZeneca$451
- Novo Nordisk$343
- Lilly USA, LLC$330
- plus $1K from 25 others
What the payments were for
- Food & beverage$5,661100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 162 | $2,019 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 52 | $856 |
| Johnson & Johnson | 22 | $519 |
| AstraZeneca | 7 | $451 |
| Novo Nordisk | 16 | $343 |
| Lilly USA, LLC | 43 | $330 |
| Pfizer | 8 | $151 |
| Novartis | 9 | $135 |
| Pharming Healthcare, Inc. | 2 | $132 |
| Kerecis Limited | 2 | $74 |
| Sanofi | 4 | $70 |
| Boehringer Ingelheim | 2 | $66 |
| Amgen | 4 | $48 |
| Actelion Pharmaceuticals US, Inc. | 4 | $47 |
| Sanofi Pasteur Inc. | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 3 | $37 |
| Abiomed | 1 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $32 |
| Gilead | 2 | $30 |
| Abbott | 2 | $30 |
| Medtronic | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Si-bone, Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Grifols USA, LLC | 1 | $13 |
| MDD US Operations, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,666 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $128,675 |
| XareltoRivaroxaban | 150 | $125,625 |
| FarxigaDapagliflozin Propanediol | 95 | $81,876 |
| JardianceEmpagliflozin | 86 | $77,876 |
| EliquisApixaban | 101 | $70,138 |
| MounjaroTirzepatide | 36 | $36,831 |
| MyrbetriqMirabegron | 73 | $25,365 |
| RybelsusSemaglutide | 13 | $24,662 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $21,797 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $21,697 |
| TrulicityDulaglutide | 21 | $20,438 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $15,728 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,403 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $14,406 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 15 | $13,720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Levemir, Novolog | $343 | $161,436142 claims |
| Johnson & JohnsonXarelto | $519 | $125,625150 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $451 | $111,705147 claims |
| Boehringer IngelheimJardiance | $66 | $77,87686 claims |
| PfizerEliquis | $151 | $70,138101 claims |
| Lilly USA, LLCMounjaro, Trulicity | $330 | $57,26957 claims |
| Astellas Pharma US IncMyrbetriq | $32 | $25,36573 claims |
| AbbVieLinzess, Synthroid | $2,019 | $11,63369 claims |
| NovartisEntresto | $135 | $6,23119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Kearney
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.